Premature Ejaculation
Conditions
Keywords
Premature Ejaculation, Lidocaine
Brief summary
The purpose of this study is to evaluate the efficacy of treatment with Promescent Lidocaine Spray compared with placebo in patients with premature ejaculation.
Detailed description
Promescent Lidocaine Spray is a non-prescription drug that is marketed under an over-the-counter drug monograph (21 CFR Section 348.10 Subpart B (a)(2)) for male genital desensitizing drug products. In addition the evaluating the efficacy of treatment with Promescent, this study will evaluate patients' subjective distress, perception of improvement and optimal dose, and safety and tolerability of Promescent for patients with premature ejaculation and their respective partners.
Interventions
DRUGPlacebo
During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
DRUGPromescent Lidocaine Spray
During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
Sponsors
Eugene Y Rhee, MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject has provided written informed consent before screening. * Subject is a male, 18 years of age or older. * Subject meets the diagnostic criteria for premature ejaculation as defined by the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; 2000). * Subject has a stable, monogamous, heterosexual relationship and sexually active for at least the last 6 months. * Subject and partner are willing and able to engage in sexual intercourse.
Exclusion criteria
* Subject has never achieved an intravaginal ejaculation during the past 6 months (i.e., always ejaculates prior to penetration). * Subject has other forms of ejaculatory dysfunction (e.g., retrograde ejaculation, anejaculation, painful ejaculation). * In the opinion of the investigator, the subject has a condition or is in a situation that may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's ability to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intravaginal Ejaculatory Latency Time (IELT) in seconds | Week 11 | The primary efficacy outcome is the proportion of subjects that achieve a mean IELT of greater than 90 seconds at Week 3, 7, and 11. |
Secondary
| Measure | Time frame |
|---|---|
| Subjective distress | Week 3, 7, and 11 |
| Perception of improvement in premature ejaculation | Week 3, 7, and 11 |
| Perceived optimal dosage of treatment | Week 3, 7, and 11 |
| Adverse events/reactions to treatments | Week 11 |
Countries
United States
Outcome results
None listed